Compare iShares International Treasury Bond ETF (IGOV) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares International Treasury Bond ETF vs Summit Therapeutics Inc — how do they compare? iShares International Treasury Bond ETF trades at $39.74 (market cap $1.30B), while Summit Therapeutics Inc trades at $17.59 (market cap $13.71B). The key difference: Summit Therapeutics Inc is far larger — about 10.5× iShares International Treasury Bond ETF's market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, iShares International Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares International Treasury Bond ETF for 92 Days and Summit Therapeutics Inc for 16 Days on average.
| IGOV | SMMT | |
|---|---|---|
Market Cap | $1.30B | $13.71B |
Volume | 693,740 | 6,173,057 |
Sector | Fixed Income | Health |
52-Week High | $42.99 | $26.38 |
52-Week Low | $39.65 | $12.43 |
Typical Hold Time | 92 Days | 16 Days |
Enterprise Value | — | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IGOV trades at $39.74 with minimal daily movement (+0.1%). Technical indicators show a bearish bias with moving averages signaling selling pressure, though oscillators remain neutral. The stock faces resistance at $40 across multiple levels, indicating consolidation. Financial ratios are unavailable in current data, limiting fundamental assessment of valuation and profitability metrics.
The bearish technical setup suggests near-term caution, though neutral RSI readings indicate potential stabilization. Rising bond yields create macroeconomic headwinds for equities, but specific company fundamentals require updated SEC filings for proper evaluation. Investment appeal hinges on upcoming earnings clarity amid broader market volatility.
Summit Therapeutics (SMMT) trades at $17.59, down 2.01% on the day, amid mixed earnings performance but strong analyst support with a consensus price target of $29.33. The stock shows a bullish technical signal from moving averages, with key support at $17 and resistance at $18. Recent news highlights a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, boosting investor optimism despite current negative profitability metrics.
The outlook for SMMT is heavily driven by clinical progress and partnerships, offering significant upside if drug trials succeed, but carries high risk due to substantial losses, negative cash flow from operations, and reliance on positive trial outcomes. Investors should weigh the potential rewards against the company's current financial health and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares International Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Read more on IGOV →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
